Toward convergence in the medication treatment of bipolar disorder and schizophrenia

Harvard Review of Psychiatry

Volumn 13, Issue 1, 2005, Pages 28-42

  Citrome, Leslie ^a,e   Goldberg, Joseph F ^b   Stahl, Stephen M ^c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^e NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Aripiprazole; Clozapine; Lithium; Mood stabilizer; Olanzapine; Quetiapine; Risperidone; Second generation antipsychotic; Valproate; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EXPOSURE; DRUG MECHANISM; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IRRITABILITY; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; UNITED STATES;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; SCHIZOPHRENIA;

EID: 15944379171     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1080/10673220590923164     Document Type: Review

References (133)

1. Pope HG Jr, Lipinski JF Jr. Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of 'schizophrenic' symptoms in the light of current research. Arch Gen Psychiatry 1978;35:811-28.
2. Citrome L. Differential diagnosis of psychosis, a brief guide for the primary care physician. Postgrad Med 1989;85:273-80.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: APA, 1980.
4. Citrome L, Volavka J. Atypical antipsychotics-evolutionary or incremental advance? Exp Rev Neurother 2002;2:69-88.
5. Citrome L, Jaffe A, Levine J. Datapoints-mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001. Psychiatr Serv 2002;53:1212.
6. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 11):1-80.
7. Bauer MS, Mitchner L. What is a mood stabilizer? An evidence-based response. Am J Psychiatry 2004;161:3-18.
8. Ghaemi SN. On defining "mood stabilizer." Bipolar Disord 2001;3:154-8.
9. Keck PE Jr., McElroy SL, Richtand N, Tohen M. What makes a drug a primary mood stabilizer? Mol Psychiatry 2002;7(suppl 1):S8-14.
10. Baldassano CF, Ballas C, Datto SM, et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Disord 2003;5:72-5.
11. Davis R, Risch SC. Ziprasidone induction of hypomania in depression? [Letter]. Am J Psychiatry 2002;159:673-4.
12. Benazzi F. Quetiapine-associated hypomania in a woman with schizoaffective disorder [Letter]. Can J Psychiatry 2001;46:182-3.
13. Baker RW, Milton DF, Stauffer VL, Gelenber A, Tohen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affect Disord 2003;73:147-53.
14. Brieger P. Hypomanic episodes after receiving ziprasidone: an unintended "on-off-on" course of treatment [Letter]. J Clin Psychiatry 2004;65:132.
15. Lu BY, Lundgren R, Escalona PR, Roberts BD. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry 2002;63:1185-6.
16. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108-12.
17. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-64.
18. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000;61:329-34.
19. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003;64:451-8.
20. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002;12:93-9.
21. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000;157:982-6.
22. Mahmood T, Devlin M, Silverstone T. Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment. Aust N Z J Psychiatry 1997;31:424-6.
23. Antonacci DJ, Swartz CM. Clozapine treatment of euphoric mania. Ann Clin Psychiatry 1995;7:203-6.
24. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-80.
25. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-4
26. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-80.
27. Vieta E, Khanna S, Van Kammen D, Lyons B, Grossman F, Kramer M. Risperidone monotherapy in acute bipolar mania [Abstract 53]. In: Proceedings of the 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December, 2002:222.
28. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.
29. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-65.
30. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-9.
31. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute mania: a double-blind, placebo-controlled study. Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9.
32. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148-55.
33. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-7.
34. Tohen M, Ketter TA, Zarate CA Jr, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1253-71.
35. Tohen M, Mameros A, Bowden C, et al. Olanzapine versus lithium in relapse prevention in bipolar disorder. Poster NR509 presented at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May 2003.
36. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003;73:155-61.
37. Baker RW, Tohen M, Fawcett J, et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003;23:132-7.
38. Baker RW, Goldberg JF, Tohen M, Milton DR, Stauffer VL, Schuh LM. Olanzapine vs. placebo: mania improvement is unaffected by response to previous mood stabilizer therapy. Bipolar Disord 2002;4:43-9.
39. Tohen M, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Poster NR197 presented at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May 2003.
40. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26.
41. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88.
42. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-8.
43. Segal S, Riesenberg RA, Ice K, English P. Ziprasidone in mania: a 21-day randomized, double-blind, placebo controlled trial. Eur Neuropsychopharmacol 2003;13(suppl 4):S345.
44. Keck PE Jr, Reeves KR, Harrigan EP. Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001;21:27-35.
45. Brecher M, Huizar K. Quetiapine vs placebo for acute mania associated with bipolar disorder (STAMP 1). Bipolar Disord 2003;5(suppl 1):P27.
46. Paulsson B, Huizar K. Quetiapine monotherapy vs placebo for acute bipolar mania (STAMP 2). Bipolar Disord 2003;5(suppl 1):P153.
47. Calabrese JR, Macfadden W, McCoy R, et al. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Poster NR756 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May 2004.
48. Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002;4:335-40.
49. Ghaemi SN, Goldberg JF, Henry CA, et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study. Bipolar Disord 2003;5(suppl 1):P73.
50. Keck PE Jr, Marcus R, Tourkodimitris S, et al. Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
51. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole versus placebo in patients with an acute manic or mixed episode. Poster NR742 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May 2004.
52. Keck, PE, Sanchez R, Marcus RN et al. Aripiprazole for relapse prevention in bipolar disorder in a 26-week trial. Poster NR746 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May 2004.
53. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
54. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;151(suppl):1-36.
55. Goldman SA. Lithium and neuroleptics in combination: the spectrum of neurotoxicity. Psychopharmacol Bull 1996;32:299-309.
56. Sernyak MJ, Godleski LS, Griffin RA, Mazure CM, Woods SW. Chronic neuroleptic exposure in bipolar outpatients. J Clin Psychiatry 1997;58:193-5.
57. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002;159(suppl):1-50.
58. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-71.
59. Zarate CA Jr, Quiroz LA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 2003;5:217-25.
60. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium or valproate monotherapy. Arch Gen Psychiatry 2002;59:62-9.
61. Sachs G, Mullen JA, Devine N, Sweitzer D. Quetiapine versus placebo as adjunct to mood stabilizer for the treatment of acute bipolar mania. Bipolar Disord 2004;6:213-23.
62. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adol Psychiatry 2002;41:1216-23.
63. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br J Psychiatry 2003;182:141-7.
64. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-54.
65. Weisler RH, Warrington L, Dunn J, English P. Adjunctive ziprasidone in bipolar mania: short-term and long-term data. Poster NR358 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May 2004.
66. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
67. Tohen M, Chengappa KNR, Suppes T, et al. Prevention of relapse in bipolar disorder with olanzapine in combination with lithium or valproate compared to lithium or valproate monotherapy: an 18-month study. Br J Psychiatry 2004;184:337-45.
68. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002;10:280-91.
69. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000;51:634-8.
70. Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. Psychopharmacology (Berl) 1993;111:359-66.
71. Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 1991;84:150-4.
72. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized clinical trials. J Clin Psychiatry 2004;65:177-86.
73. Prakash R. Lithium-responsive schizophrenia: case reports. J Clin Psychiatry 1985;46:141-2.
74. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Malden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathological outcome in schizophrenic patients. J Clin Psychopharmacol 1999;19:310-5.
75. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatr Neurosci 1992;17:1-14.
76. Luchins DL. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 1984;20:569-71.
77. Yassa R, Dupont D. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a case report. Can J Psychiatry 1983;28:566-8.
78. Hakola HPA, Laulumaa VA. Carbamazepine in treatment of violent schizophrenics [Letter]. Lancet 1982;1:1358.
79. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983;44:326-31.
80. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987;22:303-10.
81. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989;80:250-9.
82. Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry 2002;63:218-24.
83. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull 2003;37(suppl 2):74-88.
84. Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001;21:21-6.
85. Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509-23.
86. Gundurewa V, Beckmann H, Zimmer R, Ruther E. Effect of valproic acid on schizophrenic syndromes [in German]. Arzneimittelforschung Drug Res 1980;30:1212-3.
87. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-9.
88. Altamura AC, Basile R, Mauri M, Cazzullo CL. Le valpromide dans le traitment d'etats psychotiques aigus: une etude clinique ouverte [in French]. Acta Psychiatr Belg 1986;86:297-304.
89. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry 1989;11:199-207.
90. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989;9:45-8.
91. Chong SA, Tan CH, Lee EL, Liow PH. Augmentation of risperidone with valproic acid. J Clin Psychiatry 1998;59:430.
92. McElroy SL, Keck PE, Pope HG. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987;7:16-24.
93. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980;137:240-4.
94. Ko GN, Korpi ER, Freed WJ, Zalcman SJ, Bigelow LB. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenia patients. Biol Psychiatry 1985;20:209-15.
95. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998;31:122-5.
96. Wassef AA, Dott SG, Harris A, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20:357-61.
97. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia-revisited. Br J Psychiatry 1987;150:542-6.
98. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977;55:299-308.
99. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-92.
100. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004;55:290-4.
101. Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res 2004;70:33-7.
102. Citrome L, Tremeau F, Wynn PS, Roy B, Dinakar H. A study of the safety, efficacy and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J Clin Psychopharmacol 2004;24:255-9.
103. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled trial. Biol Psychiatry 2003;54:1241-8.
104. Kremer I, Vass A, Gurelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56:441-6.
105. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998;43:305.
106. Megna JL, Devitt PJ, Sauro MD, Dewan MJ. Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann Pharmacother 2002;35:12-6.
107. Jablonowski K, Margolese HC, Chouinard G. Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatry 2002;47:975-6.
108. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001;24:290-4.
109. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry 2002;159:675.
110. Baird P. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J Clin Psychopharmacol 2003;23:419.
111. Centorrino F, Albert MJ, Berry JM, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003;5:370-4.
112. Leweke FM, Gerth CW, Koethe D, Faulhaber J, Klosterkotter J. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry 2004;161:1130-1.
113. Stahl SM. Essential psychopharmacology of antipsychotics and mood stabilizers. New York: Cambridge University Press, 2002.
114. Sills GJ, Brodie MJ. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord 2001;3:165-72.
115. Manji HK, Bowden CL, Belmaker RH, eds. Bipolar medications: mechanisms of action. Washington, DC: American Psychiatric Press, 2000.
116. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry 2003;64(suppl 8):5-8.
117. Stahl SM, Shayegan DK. Psychopharmacology of ziprasidone; receptor binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(suppl 19):6-12.
118. Stahl SM. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? J Clin Psychiatry 2004;65:149-50.
119. Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug gabapentin (Neurontin) binds to the alpha 2 delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
120. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(5 suppl 2):S53-67.
121. Ketter TA, Wong PW. The emerging differential roles of GABAergic and antiglutaminergic agents in bipolar disorders. J Clin Psychiatry 2003;64(suppl 3):15-20.
122. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18)F]6-fluoro-L- dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002;159:768-74.
123. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003;23:601-40.
124. Lopez LM, Wassef AA, Molloy MS, Williams NG. Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia. Neuropsychopharmacology 2004;29:1217.
125. Winterer G, Schmitt U, Schmidt LG. Reply: valproate treatment in schizophrenia: interaction of GABA with dopamine. Neuropsychopharmacology 2004;29:1218-20.
126. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48:740-54.
127. Costa E, Chen Y, Davis J, et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Intervent 2002;2:47-57.
128. Javitt DC, Coyle JT. Decoding schizophrenia. Sci Am 2004;290(1):48-55.
129. Berrettini W. Bipolar disorder and schizophrenia: convergent molecular data. Neuromol Med 2004;5:109-17.
130. Keri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 2004;110:83-91.
131. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
132. Stahl SM. Deconstructing psychiatric disorders, part 1. Genotypes, symptom phenotypes, and endophenotypes. J Clin Psychiatry 2003;64:982-3.
133. Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry 2004;65:8-9.